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Background: Renal dysfunction is associated with a variety of cardiac alterations including left ventricular (LV)
hypertrophy, LV dilation, and reduction in systolic and diastolic function. It is common and associated with an
increased mortality risk in heart failure (HF) patients. This study was designed to evaluate whether severe diastolic
dysfunction contribute to the increased mortality risk observed in HF patients with renal dysfunction.
Methods: Using Cox Proportional Hazard Models on data (N = 669) from the EchoCardiography and Heart Outcome
Study (ECHOS) study we evaluated whether estimated glomerular filtration rate (eGFR) was associated with mortality risk
before and after adjustment for severe diastolic dysfunction. Severe diastolic dysfunction was defined by a restrictive left
ventricular filling pattern (RF) (=deceleration time < 140 ms) by Doppler echocardiography.
Results: Median eGFR was 58 ml/min/1.73 m2, left ventricular ejection fraction was 33% and RF was observed in 48%.
During the 7 year follow up period 432 patients died. Multivariable adjusted eGFR was associated with similar mortality
risk before (Hazard Ratio(HR)eGFR 10 ml increase: 0.94 (95% CI: 0.89-0.99, P = 0.024) and after (HReGFR 10 ml increase: 0.93
(0.89-0.99), P = 0.012) adjustment for RF (HR: 1.57 (1.28-1.93), P < 0.001).
Conclusions: In patients admitted with HF RF does not contribute to the increased mortality risk observed in
patients with a decreased eGFR. Factors other than severe diastolic dysfunction may explain the association
between renal function and mortality risk in HF patients.
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An association between renal dysfunction and mortality
risk has been documented several times in heart failure
(HF) patients [1-6]. The cause of excess mortality in
these patients is, however, poorly understood as is the
interplay between renal dysfunction and other prognostic
factors in HF. Several explanations – e.g. increased athero-
sclerotic burden, impaired central haemodynamics and in-
creased neurohormonal activity - have been proposed for
the increased mortality risk in HF patients with a poor
renal function [7-17]. However, an observational follow up* Correspondence: m.schou@dadlnet.dk
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reproduction in any medium, provided the orstudy, where all proposed prognostic factors in HF have
been included has not yet been conducted in a large HF
cohort and consequently it is still unclear if the effect of
renal function and mortality risk can be explained by
e.g. impaired diastolic function or other important
confounders [18].
In patients with chronic kidney disease diastolic dys-
function may be present in up to 70% of the patients
[19] and a link between renal dysfunction and left ven-
tricular hypertrophy resulting in diastolic dysfunction
may also be present in patients with HF, where renal
dysfunction is often present. In theory, renal dysfunction
could contribute to the heart failure syndrome, nega-
tively affecting prognosis, by adding the burden of im-
paired filling to patients suffering from HF. However,
studies with long-term follow-up and information onLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients.
To address these issues we used data from the Echo-
Cardiography and Heart Outcome Study (ECHOS) study
to evaluate whether the increased mortality risk ob-
served in HF patients with renal dysfunction potentially
could be explained by severe diastolic dysfunction.
Methods
Study population and patient selection
The ECHOS study was a trial of the central symphatolytic
agent CHF1035 versus placebo in patients with HF. The
trial design and results have been described in detail previ-
ously [20,21]. Briefly, from 2001 to 2002, 3954 consecutive
patients admitted with congestive HF were screened in 43
hospitals in Scandinavia, primarily Denmark. Congestive
HF was defined as current NYHA functional class II–IV,
requiring intravenous treatment with diuretic and at least
one episode of dyspnoea or fatigue at rest or during slight
exertion within the last month corresponding to at least
NYHA class III or IV). Demographic variables and comor-
bid conditions were registered (Table 1). A Wall Motion
Index (WMI) ≤ 1.2 (≈ Left ventricular ejection fraction
(LVEF) ≤ 35%) was found in 1831 patients and 1000
patients were eventually randomized in the drug trial.
Patients were randomized to either placebo (N = 499) or
a selective agonist of the pre-synaptic DA2- and α2-
receptors (N = 501) and were followed for at least
12 months. The study drug had no effect on overall mor-
tality or morbidity [20]. The study was carried out in ac-
cordance with the Declaration of Helsinki II and the study
was approved by The Ethical Committee of Copenhagen,
Denmark. The current study is based on data obtained
from screening of patients admitted with HF to the depart-
ments participating in the ECHOS study. Hence, this study
included both patients with systolic and diastolic HF.
For the present analyses, patients were selected as
follows: Of the initial 3954 patients screened for the
ECHOS study, only Danish patients were available for the
extended follow up (N = 3078). Of these patients 2881
patients had measurement of LVEF. Both LVEF and
serum(s)-creatinine were available in 2012 patients.
S-creatinine together with left ventricular filling pattern
obtained by the flow velocity across the mitral valve in
the apical 4-chamber view were available in 669 patients
(Table 1). Included (N = 669) and excluded (N = 2212)
patients were subsequently compared concerning import-
ant demographic variables (age, sex, NYHA class, WMI,
eGFR, frequency of RF (available in 967 patients), and mor-
tality risk (see Results)).
Echocardiography
Echocardiography was performed within the first 7 days
after admission. Patient history and a physical examinationwere obtained and all patients underwent 2-dimensional
baseline transthoracic echocardiography in order to deter-
mine LVEF. In addition to standard 2-dimensional echo-
cardiography the centers were also encouraged to perform
Doppler ultrasound and M-mode examinations on a vol-
untary basis. Doppler flow recordings of sufficient quality
were available for 972 patients. Echocardiograms were dig-
itized and subsequently analyzed by two experienced in-
vestigators (D.A. and J.K.) who were blinded to all clinical
data. Analyses of wall motion index (WMI) were evalu-
ated separately in a core lab. LVEF was assessed semi-
quantitatively from WMI using a 16-segment model.
Using a reverse scoring system, each of the 16 left ven-
tricular segments were assigned a descending score from 3
to −1, according to myocardial function (hyperkinesis = 3,
normokinesis = 2, hypokinesis = 1, akinesis = 0, paradoxical
motion = −1). WMI was calculated by dividing the sum
of the scores by the number of segments analyzed. Left
ventricular filling pattern was obtained by measuring
the diastolic flow velocities across the mitral valve in
the apical 4- chamber view. Effort was made to detect
maximal flow velocities during diastole with the sample
volume placed at the tip of the mitral leaflets. Deceler-
ation time of early filling (DT), peak flow velocity in
early diastole (E velocity) and peak flow velocity at
atrial contraction (A velocity) were measured as the av-
erages of five consecutive cardiac cycles. DT was mea-
sured similarly in patients with atrial fibrillation/-flutter,
but was based on averages of 5 to 10 consecutive car-
diac cycles. Cardiac cycles with fusion of early and late
velocities or with nonlinear deceleration slope were ex-
cluded. RF was considered present when deceleration
time was ≤140 ms [21].
Estimated glomerular filtration rate
Estimated glomerular filtration rate (eGFR) was calcu-
lated by the four-component Modification of Diet in
Renal Disease (MDRD) equation incorporating age, race,
sex and s-creatinine concentration [16]: eGFR = 186 *
(s-creatinine [in milligrams per decilitre])-1.154 * (age
[in years])-0.203. For women the product of the equa-
tion has to be multiplied by a correction factor of
0.742. The equation has been evaluated in heart failure
patients [22].
End points
The primary end-point was death from all causes ob-
tained from the Danish Central Personal Registry, where
all deaths in Denmark are registered within 2 weeks.
Thus, in (May 2008) the central registry provided 7 years
(median) of follow-up (range: 5.8 to 7.4 years) for pa-
tients included in the current analyses. One patient emi-
grated and was censored at time of emigration (after
472 days), no other patients were lost to follow-up.
Table 1 Patients characteristics according to groups of eGFR (N = 669)
Demographic data eGFR: < 45.0 ml/min
1.73 m2 N = 191
eGFR: 45.0-59.9 ml/min
1.73 m2 N = 162
eGFR: 60.0 – 74.9 ml/min
1.73 m2 N = 176
eGFR: ≥75.0 ml/min
1.73 m2 N = 140
P value
Clinical variables:
Age, years 78 (63–91) 75 (56–89) 72 (55–90) 68 (46–84) <0.001
Female sex,% 45 43 30 34 0.006
BMI, kg/m2 25 (19–26, 26–36) 26 (17–37) 26 (18–34) 27 (20–41) 0.058
Smoking,% 20 23 31 43 <0.001
History of HF,% 76 76 63 54 <0.001
NYHA Class,%: 0.052
I 7 9 15 15
II 65 65 62 65
III 25 25 19 20
IV 3 1 4 0
Comorbidity:
Diabetes,% 22 15 13 15 0.049
COPD,% 20 19 23 26 0.111
IHD,% 54 58 45 39 0.002
Previous MI,% 32 35 30 25 0.139
Hypertension,% 32 32 25 31 0.484
Chronic AF,% 26 21 28 19 0.313
Paroxysmal AF,% 19 22 21 21 0.801
Echocardiographic variables:
WMI, index: 1.2 (0.5–2.0) 1.1 (0.5–2.0) 1.3 (0.5–2.0) 1.4 (0.6–2.0) 0.093
LVEDD, mm 57 (42–75) 59 (41–77) 58 (42–70) 57 (42–78) 0.878
A, m/s 0.63 (0.30–1.15) 0.76 (0.30–1.33) 0.62 (0.32–1.03) 0.62 (0.33–0.96) 0.055
E/A-ratio 1.34 (0.56–3.37) 1.11 (0.57–3.11) 1.12 (0.58–3.03) 1.40 (0.60–3.12) 0.4639
Medication (discharge):
ACE-I,% 51 70 63 45 0.309
ARB,% 10 9 5 9 0.266
Beta blockers,% 49 57 45 42 0.097
Diuretics,% 95 93 89 89 0.017
Digoxin,% 37 39 47 36 0.634
Statin,% 17 20 16 23 0.470
Nitrates,% 28 23 12 17 0.001
eGFR = estimated glomerular filtration rate; BMI = Body Mass Index; History of HF = history of heart failure; NYHA class = New York Heart Association; COPD = chronic
obstructive pulmonary disease; IHD = ischemic heart disease; Previous MI = previous myocardial infarction; Chronic AF = chronic atrial fibrillation; Paroxysmal
AF = paroxysmal atrial fibrillation; WMI = wall motion index; LVEDD = left ventricular enddiastolic diameter; A = late atrial mitral Doppler peak flow velocity;
E/A-ratio = the ratio of early (E) to late atrial (A) mitral Doppler peak flow velocity; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin II
receptor blocker.
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Patients, were grouped by levels of eGFR: Group I:
eGFR < 45.0 ml/min/1.73 m2, Group II: eGFR 45.0-
59.9 ml/min/1.73 m2, Group III: eGFR 60.0-74.9 ml/
min/1.73 m2 and Group IV: eGFR ≥ 75.0 ml/min/1.73 m2.
Proportions are presented as percent and continuous vari-
ables are presented as medians with 95% confidence inter-
vals. Baseline characteristics were compared betweengroups using chi-square test for discrete variables and,
Cochran-Armitage Trend Test, Kruskal Wallis tests (non-
parametric) or one-way ANOVA (parametric) for continu-
ous variables, as appropriate. The associations between
eGFR and mortality were examined using Cox propor-
tional hazards model. Survival curves were generated by
means of Kaplan-Meier estimates, and differences in sur-
vival were compared using log-rank test. Cox proportional
E (Peak Velocity)























Figure 2 E (peak velocity) and frequency of restrictive
filling pattern.
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available clinical covariates (eGFR, age, sex, body mass
index, smoking, RF, WMI, NYHA class, diabetes, history
of hypertension, history of chronic obstructive pulmonary
disease, history of ischemic heart disease, previous MI,
and atrial fibrillation). The association between eGFR and
mortality risk was evaluated by a univariate analysis
(model 1), after adjustment for all covariates except RF
(model 2) and after adjustment for all covariates including
RF (model 3). The association between RF and mortality
risk was evaluated in a similar way (model 4–6). The as-
sumptions underlying the Cox proportional-hazards
model (proportional hazards, lack of interaction, and
linearity of continuous variables) were tested and found
to be valid. A P-value < 0.05 was considered significant
(two-sided). Analyses were performed using Statistical
Analysis Software (SAS 9.1, Cary, NC, USA).
Results
Patients characteristics
Patient characteristics according to groups of eGFR are
presented in Table 1 and Figures 1, 2, 3. Patients with a
low eGFR (group IV) were older (P < 0.001), more fre-
quently female (P < 0.001), and less frequently smokers
(P < 0.001). More frequently patients with low eGFR
suffered from diabetes (P = 0.049), had a history of HF
(P < 0.001) and ischemic heart disease (P = 0.002). Fi-
nally, patients with a low eGFR were treated with nitrates
(P = 0.001) and diuretics (P = 0.017) more frequently.
None of the Doppler parameters were affected by eGFR
(Figures 1, 2, 3), except the prevalence of RF (P = 0.049),
which increased with increasing eGFR (Figure 3).
Included (N = 669) versus excluded (N =2212) patients
The included and excluded patients did not differ with






















P = 0. 88
One-way ANOVA
Figure 1 Deceleration time.and NYHA class (P = 0.11), but differed to a minimal ex-
tent with regard to the frequency of left ventricular sys-
tolic dysfunction (41% of the included patients had a
LVEF < 0.50 compared to 35% of the excluded patients
(P = 0.003)), which may be explained by the fact that
s-creatinine was reported more frequently in the ran-











estimated glomerular filtration rate /
ml/min/1.73 m2
Figure 3 According to groups of estimated glomerular
filtration rate (Group I: eGFR < 45 ml/min/1.73 m2, Group II:
eGFR 45.0-59.9 ml/min/1.73 m2, Group III: eGFR 60–74.9 ml/
min/1.73 m2 and Group IV: eGFR >/= 75.0 ml/min/1.73 m2).
*Median and interquartil range.
Table 2 Multivariate cox proportional hazard models
Variable Hazard ratio (95%
confidence interval)
P value
Model 1: eGFR (Univariate) −2LogL: 5172
eGFReffect of a 10 ml increase 0.83 (0.79-0.87) <0.001
Model 2: eGFR + traditional
confounders
−2LogL: 4614
eGFReffect of a 10 ml increase 0.94 (0.89-0.99) 0.024
Model 3: RF (Univariate) −2LogL: 5223
RF 1.38 (1.14-1.66) <0.001
Model 4: RF + traditional
confounders
−2LogL: 4601
RF 1.54 (1.26-1.89) <0.001
Model 5: eGFR + RF + traditional
confounders
−2LogL: 4595
eGFReffect of a 10 ml increase 0.93 (0.89-0.99) 0.012
RF 1.57 (1.28-1.93) <0.001
Significant traditional confounders: age, sex, wall motion index, ischemic heart
disease, diabetes, chronic obstructive pulmonary disease and NYHA class.
Covariates were removed by backward elimination if P > 0.10.
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Kaplan-Meier plots showing mortality rates according
to groups of eGFR are presented in Figure 4 (LogRank
P < 0.001). In the follow-up period 432 patients died.
Univariate and multivariable Cox proportional hazard
models are presented in Table 2. Adjustment for RF
(model 4 versus model 5) did not affect the parameter
estimates for eGFR suggesting that the association be-
tween eGFR and mortality risk is not confounded by RF.
Nor was the opposite the case (model 2 versus model 5)
suggesting that nor is the association between RF and
mortality risk confounded by eGFR. We did not observe
any statistical interaction between eGFR, RF and mortal-
ity risk (P > 0.05) nor was any interaction between mor-
tality risk, eGFR < 30 ml/min/1.73 m2 and RF (P > 0.05)
observed. Furthermore, we did not observe any inter-
action between mortality risk, RF and ischemic versus
non-ischemic cardiomyopathy (P > 0.05), between mor-
tality risk, RF and history of hypertension (P > 0.05) and
between mortality risk, RF and LVEF > 40% (P > 0.05).
The prognostic significance of RF did, therefore, not
interact with any of these important subgroups for
which reason the patients were not divided further into
subgroups.
Discussion
Our data suggest that eGFR is associated with mortality
risk independently of RF in HF patients. We did not ob-
serve any coupling between renal function and severe
diastolic dysfunction and likely other factors than im-
paired left ventricular filling explain the association be-
tween renal function and mortality risk in HF patients.Kaplan Meier estimates 
Mortality according to  
to eGFR 
Figure 4 Kaplan Meier estimates according to groups of
estimated glomerular filtration rate (Group I: eGFR < 45 ml/min/
1.73 m2, Group II: eGFR 45.0-59.9 ml/min/1.73 m2, Group III: eGFR
60–74.9 ml/min/1.73 m2 and Group IV: eGFR >/= 75.0 ml/min/
1.73 m2).Previously, it has been observed that eGFR adds prog-
nostic information to RF in outpatients with chronic HF
and systolic dysfunction [23]. However, our data differ
from the data by Bruch et al. [23] since we investigated
patients admitted for acute decompensated heart failure
with preserved and reduced LVEF and selected death as
endpoint, in contrast to Bruch et al. [23] that selected
a composite endpoint of death, admission and heart
transplantation.
It has been repeatedly documented that eGFR is asso-
ciated with increased long term mortality risk in patients
with HF [1-6], but adjustment for diastolic function has
not been performed in previous studies. Data from the
DIG-trial has shown that renal dysfunction carried in-
cremental prognostic information in HF patients with
preserved LVEF, but diastolic function was not recorded
[6]. We observed that adjustment for RF did not affect
the parameter estimates for eGFR (Table 2). Consequently,
RF cannot explain the excess mortality associated with
renal dysfunction. Early mitral inflow peak velocity (E), E/
A-ratio and DT did not correlate to eGFR (Figures 1, 2
and Table 1), but the frequency of RF increased slightly
with increasing eGFR (Figure 3). Accordingly, the severity
of diastolic dysfunction did not increase with decreasing
eGFR. This observation may reflect that RF alone does not
reflect severity of diastolic dysfunction and intracar-
diac pressures accurately in this population [24] or that
a diuresed HF population with a high prevalence of renal
dysfunction is different from a chronic kidney disease
population with cardiac dysfunction [19]. It could, of
course also be a consequence of a type II error or selec-
tion bias. Lending indirect support to the recorded left
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as assessed by NYHA class also was unaffected by renal
function (Table 1) [25]. Finally, we did not observe any link
between eGFR and RF in patients admitted with acute de-
compensated HF (Cardio-renal syndrome Type I). How-
ever, this observation does not exclude and association in
e.g. acute and chronic reno-cardiac syndromes as previ-
ously observed [19].
Despite the close association with morality risk no
randomized clinical trials have indicated that an inter-
vention raised against renal dysfunction in HF can im-
prove outcome. In acute decompensated heart failure
ultrafiltration has been suggested to prevent deterior-
ation of eGFR [26], however, it remains to be determined
whether this improve long-term clinical outcome. Re-
cently, despite encouraging early results, an adenosine
receptor antagonist (Rolofylline) failed to improve renal
function in HF patients [27] and the role for nesiritide is
also unclear [28]. However, one non-randomized trial of
a systematic diagnostic and therapeutic approach directed
against renal dysfunction in HF patients has indicated that
it is possible to obtain a significant improvement in kidney
function [29], and in patients, where cardiac resynchroni-
zation therapy is indicated, this intervention may improve
renal function [30]. Clearly the issue is complex. In some
instances, such as during uptitration of ACE-inhibitors or
angiotensin II receptor blockers, transient increase in
s-creatinine is expected and accepted due to the well
known long term benefit in terms of reduced morbidity
and mortality. Thus, data suggest deterioration of renal
function in HF are associated with a poor outcome, but op-
timal management depends on the clinical setting e.g. epi-
sodes of decompensation and hyperkalemia versus up-
titration of an angiotensin converting inhibitor [31].
Based on the data from the present study as well as re-
sults of previous studies, eGFR may be considered inde-
pendently associated with mortality risk in HF patients.
The underlying mechanism is not clear. In particular, it
is uncertain if low eGFR is associated with mortality
mainly due to a renal factor (complicating intrinsic renal
disease) or mainly due to the fact that low eGFR reflects
low renal perfusion pressure because of poor cardiac
output (cardiac factor in turn leading to poor prognosis).
Although the present study suggest that the adverse
prognosis associated with low GFR is largely unrelated
to low LVEF or advanced diastolic dysfunction, the data
cannot determine whether the excess mortality is related
to an intrinsic renal mechanism or merely reflect a more
extensive vascular disease and thus increased risk in
these patients. It may be speculated that activation of
the renin-angiotensin-aldosterone-system (RAAS) causes
progression of renal dysfunction in HF similar to the de-
velopment of diabetic nephropathy, which is supported
by the CATS study (post myocardial infarction) [32].However, aggressive blockade of the Renin-angiotensin
II-aldosterone system (RAAS) in HF may lead to wors-
ening renal function as seen in the CHARM-added [33],
VALHeft [34] and VALLIANT [35] studies. A better un-
derstanding of the effect of RAAS inhibition on other
renal endpoints like micro- and macroalbuminuria in
HF is clearly needed [16,36,37].
Attention should be paid to some methodological limi-
tations of the present study. Our analyses are retrospect-
ive, but it seems unlikely that the observed associations
between eGFR or RF and mortality risk reflect type I er-
rors. Left ventricular filling pattern and s-creatinine data
was only available in 669 out of 2881 patients and it may
therefore be argued that our results reflect selection bias.
However, the included patients did not differ from the
excluded patients with respect to important clinical vari-
ables (internal validity acceptable) and selection bias
would only appear if the associations between eGFR and
RF or the associations between eGFR or RF and mortal-
ity risk were different in the excluded patients, which
seems unlikely. Furthermore, the prognostic significance
of RF and eGFR is in accordance with other studies
(external validity acceptable) [1,38,39]. We used eGFR as
estimate for GFR, and we did not analyze s-creatinine in a
core lab, and this could lead to analytical variation. Fur-
thermore, we defined severe diastolic dysfunction solely
by RF and do not have data on left atria volume, left ven-
tricular hypertrophy or tissue Doppler variables and it
may therefore be argued that our results reflect inaccurate
measurement of GFR and misclassification of severe dia-
stolic dysfunction. However, recently it has been ques-
tioned whether a gold standard for diastolic function
exists at all [40] and RF may be a reasonable estimate due
to its extensive documented association with mortality risk
in patients with HF and myocardial infarction [35,36].
Though, misclassification of severe diastolic dysfunction
may have occurred due to lack of data on left atria volume,
left ventricular hypertrophy and tissue Doppler. Patients
with HF and preserved ejection (35% of the present
patients) constitute an inhomogeneous group and it may
be argued that our results to some degree could reflect
misclassification of HF [41]. The generalizability of our re-
sults should, therefore, be noticed. The present cohort nei-
ther reflects a cohort of acute decompensated HF patients
with a reduced LVEF which are e.g “cold and wet” nor a
cohort of patients with concentric left ventricular hyper-
trophy, normal LVEF and HF symptoms, rather it is a co-
hort of patients with dyspnoea requiring diuretics (“warm
and wet”). The strengths of our study are the relatively
large sample size with data on both eGFR and RF, the in-
clusion of patients with s-creatinine data > 200 umol/L
(data from a screening database and not from a trial data-
base), the long term follow up period without any lost to
follow up and the large number of events.
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In HF patients restrictive filling of the left ventricle does
not explain the increased mortality risk observed with
decreasing eGFR. Factors other than impaired left ven-
tricular filling explain the association between renal dys-
function and mortality risk. Whether the effect of eGFR
and mortality risk in HF per se is causal deserves further
study as does the association between eGFR and diastolic
function in HF.
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